A phase I study of an IDO-1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer

Source
Journal of immunotherapy (Hagerstown, Md. : 1997) - ISSN 1524-9557-44:7 (2021) p. 264-275
Author(s)
    Nuria Kotecki, Perrine Vuagnat, Bert H. O'Neil, Shadia Jalal, Sylvie Rottey, Hans Prenen, Karim A. Benhadji, Meng Xia, Anna M. Szpurka, Abhijoy Saha, Johan Wallin, Subha Suriyapperuma, Violeta R. Galvao, Sandaruwan Geeganage, Thompson N. Doman, Leena Gandhi, Xiaojian Xu, Johanna Bendell

The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer

Source
Cancer chemotherapy and pharmacology - ISSN 0344-5704- (2021) p.
Author(s)
    Michael Z. Liao, Hans Prenen, Sandeep Dutta, Vijay V. Upreti

Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer : a randomised crossover pharmacokinetic study

Source
British journal of clinical pharmacology - ISSN 0306-5251- (2021) p.
Author(s)
    Christopher G.C.A. Jackson, Tak Hung, Eva Segelov, Paula Barlow, Hans Prenen, Blair McLaren, Noelyn Anne Hung, Katriona Clarke, Tsu-Yi Chao, Ming-Shen Dai, Hsien-Tang Yeh, David L. Cutler, Douglas Kramer, Jimmy He, Jay Zhi, Wing-Kai Chan, Rudolf Kwan, Sanjeev Deva

Neoadjuvant therapy for locally advanced rectal cancer : recent advances and ongoing challenges

Source
Clinical colorectal cancer - ISSN 1533-0028-20:1 (2021) p. 29-41
Author(s)
    Amy Body, Hans Prenen, Marissa Lam, Amy Davies, Samuel Tipping-Smith, Caroline Lum, Elizabeth Liow, Eva Segelov